Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2009-10-31
Target enrollment:
Participant gender:
Summary
This study determines the proportion of metastatic breast cancer patients progression free
after 6 months when treated with gemcitabine/ cisplatin/ trastuzumab or gemcitabine/
trastuzumab.